Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number of somatic mutations per DNA megabase (Mb)—has emerged as a proxy for neoantigen burden that is an independent biomarker associated with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Klempner, Samuel J., Fabrizio, David, Bane, Shalmali, Reinhart, Marcia, Peoples, Tim, Ali, Siraj M., Sokol, Ethan S., Frampton, Garrett, Schrock, Alexa B., Anhorn, Rachel, Reddy, Prasanth
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Immuno‐oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964127/
https://ncbi.nlm.nih.gov/pubmed/31578273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0244
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados